FDA approves MYOV’s Orgovyx (relugolix) for prostate cancer: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer An oral option for androgen deprivation is especially useful during a pandemic.